Gynecologic Cancers

Copper intrauterine device users were found to have a lower risk of high-grade cervical neoplasms compared with levonorgestrel-releasing intrauterine system users.

These findings indicate that bone mineral density screening and pharmacologic intervention should be strongly considered for these high-risk women.

The FDA granted fast track designation to balstilimab and zalifrelimab based on comprehensive data found to support their potential as a combination therapy.

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.

This study suggested that the National Comprehensive Cancer Network Distress Thermometer problem list does not easily identify concerns most associated with high distress and low quality of life in women with gynecologic cancers.

These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.

Niraparib was approved by the (FDA) for previously treated advanced ovarian, fallopian, or primary peritoneal cancers.

COX7RP contributes to endometrial and breast cancer growth.

Diagnosis of endometrial carcinoma made easier by analysis of mutations in cervix or endometrial tissue.

Immunotherapy could replace chemotherapy in some patients with recurrent/metastatic cervical and vaginal or vulvar cancers.

Researchers examined the results of ribociclib and letrozole as a treatment for patients with estrogen receptor-positive ovarian cancer and endometrial cancer.

The US Food and Drug Administration recently approved a new indication for olaparib for maintenance treatment in adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer.

How much do you know about predicting patient outcomes in ovarian cancer? Take our latest quiz to test your knowledge.

Significant reductions in several strains of HPV and HPV-associated diseases have occurred in the up to 8 years of follow-up since implementation of the girls-only HPV vaccination.

A new study reinforces the need for universal mismatch repair protein immunohistochemistry screening of tumors from endometrial cancer patients, as well as germline genetic testing in accordance with guidelines.

Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer.

A phase I/II trial tested the combination of niraparib and pembrolizumab in patients with recurrent ovarian carcinoma.

Dr. Makker summarizes the standard of care for the treatment of advanced endometrial cancer, with a look forward to the multitude of clinical trials evaluating novel therapy combinations that are currently enrolling patients or underway.

How much do you know about the link between various germline mutations and ovarian cancer? Take our latest quiz to test your knowledge.

An analysis of the phase III SOLO1 trial examined safety signals with olaparib maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation.

A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer.

Researchers analyzed recurrence and survival outcomes for clear cell ovarian carcinoma in the JGOG3017/GCIG trial.

Cancer Network spoke with Yoland Catherine Antill, MD, of Cabrini Health, about the phase II PHAEDRA trial, which tested the activity of durvalumab in advanced endometrial cancer according to mismatch repair status.

Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer who experienced response to platinum-based chemotherapy.

Cancer Network spoke with Patricia Eifel, MD, of the University of Texas MD Anderson Cancer Center, about the current shifts in the treatment of cervical cancer.

This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer.

Data from a phase II study were presented at ASCO 2019, focusing on responses among women with BRCA wild-type ovarian cancer to olaparib.

The EWOC-1 trial looked at single-agent carboplatin in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer vs weekly or every 3 weeks carboplatin/paclitaxel.

The phase II AVANOVA trial examined PFS in advanced ovarian cancer patients who received a PARP inhibitor plus bevacizumab.